You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

As a result of its solid and successful experience as partner with the Italian Health System, its significant expansion into international operations and a fundamental commitment to research and development, Kedrion’s line of plasma-derived products is broad and diverse.

With treatments for many rare and debilitating diseases and conditions from hemolytic disease in newborns to immune deficiencies to hemophilia, Kedrion offers a wide and expanding array of treatments and therapies.

PRODUCT PORTFOLIO

HEMATOLOGY/HEMOPHILIA

PLASMACLOT 250 UI
Factor VIII/von Willebrand Factor concentrate. Key number of reimbursement at "Cuadro Básico de Medicamentos": 4239 F8

KEDRIFIX 500 UI
Factor XI concentrate. Key number of reimbursement at "Cuadro Básico de Medicamentos": 5238 F9

Immunology/Neurology

KEDRIGAMMA 5G/6G
Standard i.v.Immunoglobulin. Key number of reimbursement at "Cuadro Básico de Medicamentos": 5244 IG5;  5240 IG6    

KeyRho            
Anti-D i.m. Immunoglobulin. Key number of reimbursement at "Cuadro Básico de Medicamentos": 1591 IGD  

 

CRITICAL CARE

KEDRIALB 20% 25%
Human Albumin solution. Key number of reimbursement at "Cuadro Básico de Medicamentos": 4552 A20; 3662 A25      

ORPHAN DRUGS

Kedrion Human Plasminogen: a sterile human plasma derived plasminogen preparation in the pharmaceutical form of an eye drop solution for the treatment of Ligneous Conjunctivitis (currently under development product).
At the moment the product obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The clinical trial is still ongoing for the Marketing Authorization approval in the USA and in Europe (EU).